Thromboelastography (TEG) was studied as a tool for evaluating venous thromboembolism (VTE) risk in female cancer patients undergoing chemotherapy. TEG parameters were used to assess hypercoagulability, with 63% of patients showing this after the first cycle and 75% after the second cycle. Patients with ovarian cancer had higher TEG values compared to those with breast or endometrial cancer. Patients with high-risk Khorana scores also had higher TEG values. VTE occurred in 14% of patients, with a significant correlation with a history of platinum-based chemotherapy. The study concluded that TEG could be a useful biomarker for assessing VTE risk in female cancer patients.
Source link
Thromboelastography Promising as Risk Assessment for VTE in Women’s Cancers
